

PACIFIC DIAGNOSTIC LABORATORIES  
 GVCH only  
 Antimicrobial Susceptibility Profile January thru December 2010  
 Percent Susceptible<sup>1</sup>

| ORGANISM <sup>1</sup>                  | AVG. SAMPLE SIZE | AMPICILLIN | AMP / SUL  | NAFCIL/OXACIL | PIP / TAZO | TETRACYCLINE | CEFAZOLIN  | TIGECYCLINE | CEFOTETAN | CEFTAZIDIME | CEFTRIAXONE | CIPROFLOXACIN | LEVOFLOXACIN          | GENTAMICIN | IMPENEM | ERTAPENEM | TRIMET/SULFA | NITROFURAN (3) | CLINDAMYCIN | ERYTHROMYCIN | VANCOMYCIN | LINEZOLID  | RIFAMPIN (4) |
|--|------------------|------------|------------|---------------|------------|--------------|------------|-------------|-----------|-------------|-------------|---------------|-----------------------|------------|---------|-----------|--------------|----------------|-------------|--------------|------------|------------|--------------|
| <i>Escherichia coli</i>                | 411              | 54         | 67         |               | 97         |              | 93         | 100         | 97        | 96          | 97          | 78            | 78                    | 91         | 100     | 100       | 74           | 93             |             |              |            |            |              |
| <i>Klebsiella species</i>              | 76               | 0          | 92         |               | 100        |              | 92         | 99          | 99        | 96          | 97          | 96            | 97                    | 100        | 100     | 100       | 91           | 29             |             |              |            |            |              |
| <i>Pseudomonas aeruginosa</i>          | 236              |            | 69         |               | 0          |              | 0          | 67          |           | 63          |             | 63            |                       | 71         | 84      |           |              |                |             |              |            |            |              |
| <i>Proteus mirabilis</i>               | 122              | 27         | 45         |               | 92         |              | 65         | 70          | 77        | 70          | 69          | 66            | 65                    | 83         | 100     | 100       | 27           | 0              |             |              |            |            |              |
| <b>Staphylococcus aureus (overall)</b> | <b>720</b>       |            | <b>(2)</b> | <b>62</b>     |            | <b>89</b>    | <b>(2)</b> |             |           |             |             |               | <b>60<sup>b</sup></b> | <b>98</b>  |         |           | <b>98</b>    | <b>96</b>      | <b>79</b>   | <b>47</b>    | <b>100</b> | <b>100</b> | <b>99</b>    |
| <b>Staphylococcus aureus (MSSA)</b>    | <b>447</b>       |            |            | <b>100</b>    |            | <b>92</b>    |            |             |           |             |             |               | <b>87<sup>b</sup></b> | <b>99</b>  |         |           | <b>99</b>    | <b>94</b>      | <b>87</b>   | <b>70</b>    | <b>100</b> | <b>100</b> | <b>100</b>   |
| <b>Staphylococcus aureus(MRSA)</b>     | <b>273</b>       |            |            | <b>0</b>      |            | <b>84</b>    | <b>0</b>   |             |           |             |             |               | <b>15<sup>b</sup></b> | <b>97</b>  |         |           | <b>95</b>    | <b>99</b>      | <b>66</b>   | <b>10</b>    | <b>100</b> | <b>100</b> | <b>97</b>    |
| <b>Enterococcus species</b>            | <b>70</b>        | <b>94</b>  |            |               |            |              |            |             |           |             |             |               | <b>(5)</b>            |            |         |           |              |                |             |              | <b>100</b> | <b>76</b>  |              |

**Footnotes:**

1. Profiles include data from disk diffusion, automated testing and gradient diffusion MIC. Intermediate results have been interpreted as resistant for this tabulation. All isolates were not tested against each antibiotic in the profile.
2. Refer to oxacillin results. Oxacillin resistant strains may not respond to beta lactam antibiotics such as penicillins, cephalosporins and imipenem.
3. Data apply only to organisms isolated from urinary tract.
4. Rifampin should not be used as a sole agent for antimicrobial therapy.
5. Fluoroquinolones are generally not an appropriate therapy against enterococcus infections from sites other than urine.
6. Staphylococcus isolates may become resistant to fluoroquinolones within 3-4 days after initiation of therapy. (NCCLS M100-S14,2004)

**PACIFIC DIAGNOSTIC LABORATORIES  
SANTA BARBARA, CA**

**ANTIBIOTIC SUSCEPTIBILITY PROFILES  
2010  
GVCH location only**

**DEPARTMENTS OF MICROBIOLOGY**

**MANAGER**

**Marian Jean, CLS(ASCP)  
805-879-8185  
Email (mjean@sbch.org)**